Full-Time

Head – Quality Management Systems

Updated on 1/16/2025

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

51-200 employees

Develops treatments for neurodegenerative diseases

Biotechnology
Healthcare

Expert

Remote in USA

Must reside and work within the United States in a state where Amylyx currently does business.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • B.S. in Pharmaceutical Sciences (advanced degree a plus)
  • Minimum 10-12 years of experience within the Pharmaceutical or Biotechnology industry in a quality role
  • Working knowledge of QMS electronic platforms e.g. Veeva, Pilgrim, TrackWise, ZenQMS, etc.
  • Ability to work with all levels of the organization and external contract service providers to ensure compliance with current regulations
  • Experience in developing and implementing GxP quality systems to meet regulatory and industry standards
  • Knowledgeable in FDA cGMP regulations, Eudralex and ICH Guidance, as well as other Biopharma industry guidance and regulations
  • Experience in supporting functions during FDA, EMA or other regulatory agency inspections
Responsibilities
  • Manage implementation, validation, and management for deviations, CAPA, Complaints and Change Control
  • Monitor the overall health of the QMS, generate KPIs and drive continuous improvement of the QMS
  • Responsible for Quality oversight of Data Integrity and Computer System Validation activities
  • Approve and review non-compliance events, for example, deviations, OOS, investigations, etc. that occur during production and testing, investigate and support remediation
  • Oversee operations of the Document Control and Records Management and the Training and Personnel Qualification processes
  • Develop training strategies and materials that support GXP activities, including continuous improvement initiatives
  • Write, review and/or approve SOPs for QA clinical and commercial systems e.g. software usage, complaints, annual product review
  • Provide system oversight and ensure system compliance and usage to regulatory and corporate requirements as they related to document control and records management
  • Manage Annual Product Quality Reviews
  • Support cross functional teams in processing document requests, document approval, and document archival
  • Support implementation and qualification of software for Quality Management Systems
  • Review and approve SOPs for quality
  • Support quality improvements to maintain compliance and improve efficiency as part of continuous improvement initiatives
  • Represents Amylyx QA. Creates Agendas and manage resources to drive Amylyx needs and timelines
  • Promote a Culture of Quality through collaboration
Desired Qualifications
  • Experience managing people and/or multi-functional projects preferred
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes and enhance the quality of life for individuals suffering from neurodegenerative conditions.

Company Stage

IPO

Total Funding

$166.7M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

-13%

1 year growth

5%

2 year growth

8%
Simplify Jobs

Simplify's Take

What believers are saying

  • Positive Phase II results for AMX0035 in ALS boost its potential market approval.
  • Growing interest in combination therapies aligns with Amylyx's AMX0035 strategy.
  • FDA's emphasis on accelerated approval pathways could expedite Amylyx's drug approvals.

What critics are saying

  • Failure of Phase III PHOENIX trial for Relyvrio impacts Amylyx's reputation and future approvals.
  • Acquisition of avexitide could strain financial resources if Phase 3 trials underperform.
  • Public offering at $3.50 per share may indicate financial instability, affecting investor confidence.

What makes Amylyx Pharmaceuticals unique

  • Amylyx focuses on neurodegenerative diseases like ALS and Alzheimer's, unlike many competitors.
  • AMX0035 combines sodium phenylbutyrate and taurursodiol, a unique approach in neurodegenerative treatment.
  • Amylyx engages in community awareness campaigns, enhancing its brand and patient engagement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options